| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
159,210,000 |
| Market
Cap: |
1.08(B) |
| Last
Volume: |
2,204,422 |
Avg
Vol: |
2,198,299 |
| 52
Week Range: |
$1.78 - $6.34 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reasons Bryan M. |
Chief Financial Officer |
• • – |
2013-10-26 |
4 |
D |
$20.47 |
$19,221 |
D/D |
(939) |
35,302 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-10-25 |
4 |
A |
$0.00 |
$0 |
I/I |
16,900 |
161,832 |
|
- |
|
| Ben-Maimon Carole |
President, Global Pharm. |
• • – |
2013-10-25 |
4 |
OE |
$18.93 |
$127,475 |
D/D |
6,734 |
62,914 |
|
- |
|
| Ben-Maimon Carole |
President, Global Pharm. |
• • – |
2013-10-10 |
4 |
OE |
$18.93 |
$99,988 |
D/D |
5,282 |
56,180 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-10-09 |
4 |
AS |
$20.10 |
$30,150 |
D/D |
(1,500) |
48,325 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-09-18 |
4 |
GD |
$0.00 |
$0 |
I/I |
250 |
2,309,658 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-09-11 |
4 |
AS |
$20.87 |
$31,305 |
D/D |
(1,500) |
49,825 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-08-14 |
4 |
AS |
$21.15 |
$31,725 |
D/D |
(1,500) |
51,325 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-07-10 |
4 |
AS |
$20.26 |
$30,390 |
D/D |
(1,500) |
52,825 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2013-07-08 |
4 |
D |
$20.33 |
$55,951 |
D/D |
(2,752) |
58,169 |
|
- |
|
| Pendergast Mary K |
Director |
• • – |
2013-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,700 |
5,700 |
|
- |
|
| Burr Robert L |
Director |
• • – |
2013-06-12 |
4 |
AS |
$18.80 |
$28,200 |
D/D |
(1,500) |
54,325 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2013-05-28 |
4 |
AS |
$18.89 |
$12,581 |
D/D |
(666) |
40,685 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2013-05-26 |
4 |
D |
$18.80 |
$22,767 |
D/D |
(1,211) |
86,133 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-05-26 |
4 |
D |
$18.80 |
$112,819 |
D/D |
(6,001) |
677,954 |
|
- |
|
| Schlossberg Mark A |
SVP and General Counsel |
• • – |
2013-05-23 |
4 |
D |
$18.60 |
$14,787 |
D/D |
(795) |
60,921 |
|
- |
|
| Ben-Maimon Carole |
President, Global Pharm. |
• • – |
2013-05-23 |
4 |
D |
$18.60 |
$7,421 |
D/D |
(399) |
50,898 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-05-23 |
4 |
D |
$18.60 |
$111,619 |
D/D |
(6,001) |
683,955 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2013-05-23 |
4 |
D |
$18.60 |
$22,190 |
D/D |
(1,193) |
87,344 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. |
• • – |
2013-05-20 |
4 |
D |
$18.43 |
$21,987 |
D/D |
(1,193) |
88,537 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-05-20 |
4 |
D |
$18.43 |
$331,795 |
D/D |
(18,003) |
689,956 |
|
- |
|
| Terreri Peter R |
Director |
• • – |
2013-05-20 |
4 |
AS |
$18.44 |
$12,281 |
D/D |
(666) |
41,351 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
92,900 |
707,959 |
|
- |
|
| Fleming Nigel |
Director |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,700 |
13,699 |
|
- |
|
| Markbreiter Michael |
Director |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,700 |
13,699 |
|
- |
|
531 Records found
|
|
Page 10 of 22 |
|
|
0.55 (8.86%) 
